Autoimmune Gastritis (AIG) — Comprehensive Research Report

1. Disease Information

Overview. Autoimmune gastritis (AIG) — also termed Type A gastritis, autoimmune metaplastic atrophic gastritis (AMAG), or chronic autoimmune atrophic gastritis — is a chronic, organ-specific autoimmune disease of the stomach in which autoreactive CD4+ T cells and autoantibodies destroy the acid-secreting parietal cells and intrinsic-factor-producing cells of the oxyntic (corpus/fundic) mucosa, sparing the antrum (Lenti et al., 2019, PMC; Ku PMC10378041). Progressive parietal cell loss produces achlorhydria, hypergastrinemia, oxyntic atrophy, intestinal/pseudopyloric metaplasia, and — via loss of intrinsic factor — vitamin B12 malabsorption culminating in pernicious anemia. Compensatory hypergastrinemia drives enterochromaffin-like (ECL) cell hyperplasia and predisposes to type 1 gastric neuroendocrine tumors (gNETs) as well as gastric adenocarcinoma (Frontiers 2026; Naples review, PMC12563516).

Identifiers. - No single dedicated MONDO/OMIM/Orphanet term captures "autoimmune gastritis" as its own top-level rare-disease entity; instead the entity is most often indexed through its end-organ consequence, pernicious anemia: Orphanet ORPHA:120 — "Pernicious anemia," explicitly flagged by Orphanet as "NON RARE IN EUROPE" and listed with synonyms "Addison-Biermer anemia," "Biermer disease," "acquired pernicious anemia," "juvenile onset pernicious anemia" (Orphanet, ORPHA:120). - Juvenile/early-onset pernicious anemia forms are catalogued in OMIM under the 261xxx congenital vitamin-B12-malabsorption/pernicious-anemia series (e.g., an entry around OMIM:261100); because these OMIM entries emphasize monogenic juvenile pernicious anemia rather than the adult autoimmune-mediated form, they should be treated as adjacent/partially-overlapping identifiers rather than a direct MONDO-equivalent for adult AIG — this should be independently verified against the live OMIM/MONDO record before being used as a KB mappings value. - MeSH: "Gastritis, Atrophic" (D005704) is the closest controlled MeSH heading; "Anemia, Pernicious" (D000752) covers the hematologic sequela. - ICD-10/11: ICD-10 K29.4 "Chronic atrophic gastritis"; ICD-11 DA42.2/related autoimmune-gastritis coding under digestive-system chronic gastritis; pernicious anemia is coded separately (ICD-10 D51.0). - Synonyms: Type A gastritis, autoimmune metaplastic atrophic gastritis (AMAG), autoimmune corpus-restricted (chronic) atrophic gastritis, autoimmune atrophic gastritis (AAG).

Data source type. Most of the literature synthesized below is aggregated disease-level evidence (cohort studies, systematic/position-paper reviews, GWAS meta-analyses of population biobanks — Estonian Biobank, UK Biobank, FinnGen) rather than individual EHR-level curation; a few large single/multi-institution retrospective cohorts (e.g., Italian, Japanese, Chinese series) are cited explicitly below.

2. Etiology

Primary causal mechanism. AIG is caused by a breakdown of self-tolerance to the gastric H⁺/K⁺-ATPase proton pump (the α- and β-subunits) on parietal cells and, in a subset, to intrinsic factor. Autoreactive CD4+ T cells (Th1, and Th17) recognize H⁺/K⁺-ATPase-derived peptides, secrete IFN-γ/IL-17, and mediate parietal cell apoptosis via Fas-FasL and perforin/granzyme B pathways; B cells produce complement-fixing anti-parietal-cell antibodies (PCA) and anti-intrinsic-factor antibodies (IFA) (Unraveling the Mysteries of AIG, PMC11899966; Immunological mechanisms of AIG, PMC12909420).

Genetic risk factors. - A 2021 genome-wide association meta-analysis (2,166 pernicious-anemia cases vs. 659,516 European controls pooled from the Estonian Biobank, UK Biobank, and FinnGen) identified five genome-wide-significant risk loci (Lahtela et al. 2021, Nature Communications, PMC8213695; PMID not directly retrieved but paper is Nat Commun 2021;12:3811): | Locus | Lead SNP | Gene | P-value | OR (95% CI) | |---|---|---|---|---| | 1p13.2 | rs6679677 | PTPN22 | 1.91×10⁻²⁴ | 1.63 (1.48–1.79) | | 2p16.1 | rs12616502 | PNPT1 | 3.14×10⁻⁸ | 1.70 (1.41–2.05) | | 6p21.32 | rs28414666 | HLA-DQB1 | 1.40×10⁻¹⁶ | 1.38 (1.28–1.49) | | 10p15.1 | rs2476491 | IL2RA | 1.90×10⁻⁸ | 1.22 (1.14–1.30) | | 21q22.3 | rs74203920 | AIRE (missense) | 2.33×10⁻⁹ | 1.83 (1.50–2.29) |

Direct quote: "We conduct a genome-wide association study meta-analysis in 2166 cases and 659,516 European controls from population-based biobanks and identify genome-wide significant signals." The PTPN22 lead SNP (rs6679677) is in strong LD with the well-known autoimmunity nonsynonymous variant rs2476601 in exon 12 of PTPN22, also implicated in rheumatoid arthritis, SLE, type 1 diabetes, vitiligo, and autoimmune thyroid disease. - HLA class II susceptibility alleles HLA-DRB1*03 and HLA-DRB1*04 are consistently reported as increasing risk, and the HLA-DR15 haplotype has been implicated by GWAS as well (Frontiers 2026; medRxiv preprint on HLA-DR15). - AIRE missense variants link AIG/pernicious anemia to the broader monogenic autoimmune polyendocrine syndrome type 1 (APS-1/APECED) spectrum, where recurrent AIRE loss-of-function alleles (R139X, R257X, W78R, C322fsX372, T16M, R203X, A21V in an Italian APS-1 cohort, n=158) predispose to AIG among other organ-specific autoimmunities. - Candidate/proton-pump genes: ATP4A, ATP4B (the antigen itself), plus SLC26A7, SLC26A9, SLC4A2 (acid-base transporters) and BACH2 (a broad autoimmunity susceptibility transcription factor) have emerging GWAS/candidate-gene support (Kalkan et al. 2023, PMC10378041; PMID: 37504250).

Environmental/infectious risk factors. - Helicobacter pylori is the leading environmental trigger hypothesis via molecular mimicry: the β-subunit of H. pylori urease shares high sequence homology with the β-subunit of gastric H⁺/K⁺-ATPase, generating cross-reactive T- and B-cell responses in genetically susceptible hosts (MDPI review PMID unlisted). Paradoxically, the relationship between active H. pylori infection and established AIG is complex/inverse in some cohorts — chronic H. pylori infection may itself trigger AIG onset, but established AIG is often H. pylori-negative at diagnosis, and some evidence suggests H. pylori-driven Th2 responses may suppress ongoing AIG in certain contexts. - Murine roseolovirus neonatal infection triggers CD4+ T-cell-dependent gastritis in mouse models, suggesting viral triggers merit further study in humans. - Smoking: not established as a direct AIG-specific trigger but is a well-documented independent and interactive risk factor for gastric atrophy, intestinal metaplasia, dysplasia, and gastric cancer, relevant to AIG's malignant-transformation risk. - Age and sex: female sex and age >50–60 are strong epidemiological risk correlates (see Section 9). - Family history / other autoimmunity: family clustering with autoimmune thyroid disease, type 1 diabetes, vitiligo strongly increases risk (see Section 9).

Protective factors. No validated protective genetic variant is established specifically for AIG; broadly, non-risk HLA haplotypes and, per emerging microbiome data, an intact butyrate-producing gut microbiota (e.g., Faecalibacterium prausnitzii) that sustains regulatory T cell (Treg) differentiation via short-chain fatty acids is hypothesized to be protective against Th17-driven progression (Frontiers 2026).

Gene-environment interaction. The PTPN22/HLA-DQB1/AIRE genetic background is proposed to lower the threshold for H. pylori-triggered molecular mimicry and epitope spreading to become self-perpetuating autoimmunity — i.e., infection acts as an environmental "second hit" in a genetically primed host, though this remains a mechanistic hypothesis rather than a proven causal chain in humans (a KNOWLEDGE_GAP/HUMAN_MODEL_MISMATCH candidate for KB curation).

3. Phenotypes

Most AIG is asymptomatic/subclinical for years; phenotypes span GI, hematologic, neurologic, and — indirectly — endocrine/dermatologic domains via associated autoimmunity.

Table (click to expand)

Phenotype	Type	Onset/course	Frequency	Suggested HPO term
Dyspepsia / early satiety / postprandial fullness	Symptom	Adult, chronic/fluctuating	~47–60% (more common in young women, non-smokers)	HP:0002018 (Dyspepsia)
Iron-deficiency anemia	Laboratory abnormality	Often precedes B12 deficiency by years	~20–50%	HP:0011870 (Iron deficiency anemia)
Vitamin B12 deficiency / megaloblastic (pernicious) anemia	Laboratory/clinical sign	Insidious, adult (often 60s), progressive if untreated	Defining late feature	HP:0008163 (Decreased vitamin B12), HP:0001887 (Megaloblastic anemia)
Achlorhydria / hypochlorhydria	Laboratory abnormality	Progressive with atrophy	Near-universal in advanced disease	HP:0003204 (Achlorhydria, if modeled)
Hypergastrinemia	Laboratory abnormality	Compensatory, progressive	Near-universal in advanced disease	HP:0500152 (Abnormal circulating gastrin concentration) or similar
Gastric mucosal atrophy (oxyntic)	Histopathologic sign	Chronic, progressive (early→florid→end-stage over ~3 years per prospective cohorts)	Defining lesion	HP:0002608 (Atrophic gastritis, if present) / MONDO cross-ref
Glossitis	Physical sign	Secondary to B12/iron deficiency	Variable	HP:0000216 (Glossitis)
Peripheral neuropathy / paresthesia	Symptom/sign	Subacute, progressive if untreated	Occurs with B12 deficiency	HP:0003676 (Progressive; use with HP:0003390 Paresthesia)
Subacute combined degeneration of the spinal cord	Clinical sign	Late, progressive, potentially irreversible	Uncommon but serious	HP:0002314 (Subacute combined degeneration)
Ataxia	Sign	Progressive, B12-deficiency-related	Uncommon	HP:0001251 (Ataxia)
Type 1 gastric neuroendocrine tumor (ECL-cell carcinoid)	Neoplastic complication	Late, indolent	~2.8–11% cumulative (up to ~37% in some Chinese cohorts using sensitive detection)	HP:0100633 (Neuroendocrine neoplasm)
Gastric adenocarcinoma	Neoplastic complication	Late, age >60 highest risk	~0.1–0.5%/year incidence; 3–5x general population risk	HP:0012126 (Gastric adenocarcinoma, if available) / MONDO
Infertility / recurrent miscarriage	Reproductive phenotype	Adult women	Reported in case series (n=168)	HP:0000789 (Infertility)
Weight loss	Symptom	Variable	Minority	HP:0001824 (Weight loss)
Diarrhea	Symptom	Variable	Minority, malabsorption-related	HP:0002014 (Diarrhea)

Age of onset: Classically adult-onset (median age at diagnosis 61–67 years, range 18–94), but pediatric AIG is increasingly recognized — pediatric prevalence ~0.15% among children undergoing gastric biopsy, mean diagnosis age 10.9 years, with striking 68.2% female predominance and 59.1% presenting with a concurrent extragastric autoimmune disorder (Kalkan et al., PMC10378041).

Severity/progression: A prospective cohort of 270 patients found histopathology in all patients progressed over time (generally within 3 years) from mild to severe/end-stage, with no observed spontaneous regression — supporting a monotonically progressive natural history once autoimmunity is established (PMC8414617). A separate prospective study reported an annual progression rate of 10.9% from "potential" (seropositive, histologically normal) to "overt" AAG (PMID: 38050966).

Quality of life: Neurological B12-deficiency sequelae, if diagnosis is delayed, are described as "inexorably progressive," while early diagnosis and lifelong B12 replacement largely normalizes hematologic and neurologic function; dyspeptic symptoms in early disease modestly affect quality of life but are frequently under-recognized because most patients are asymptomatic.

4. Genetic/Molecular Information

AIG is a complex/polygenic autoimmune disease, not a single-gene Mendelian disorder (contrast with monogenic APS-1/AIRE, which is a Mendelian cause of syndromic AIG).

Causal antigen genes (autoantigen targets, not classically "causal mutations"): ATP4A (HGNC:816, H⁺/K⁺-ATPase α-subunit) and ATP4B (HGNC:817, β-subunit) encode the gastric proton pump targeted by PCA; intrinsic factor is encoded by GIF (HGNC:4256).
Susceptibility loci (GWAS-confirmed, see Section 2): PTPN22 (HGNC:9646), PNPT1 (HGNC:23349), HLA-DQB1 (HGNC:4944), IL2RA (HGNC:6008), AIRE (HGNC:360).
Variant classification: The PTPN22 signal tags the well-characterized rs2476601 (R620W) gain-of-function/loss-of-inhibitory-function missense variant recurrent across autoimmune disease (not AIG-specific, pleiotropic risk allele — not a Mendelian pathogenic variant in the ACMG sense). The AIRE signal (rs74203920) is annotated as missense in the GWAS meta-analysis; distinct, more severe AIRE loss-of-function alleles (R139X, W78R, R257X, C322fsX372, etc.) cause monogenic APS-1/APECED, of which AIG is one of several organ-specific autoimmune components.
Allele frequency: The PTPN22 rs2476601 minor allele frequency is well characterized in European populations (~10–12% in gnomAD/1000 Genomes; enriched across multiple autoimmune GWAS) — population-level data should be pulled from gnomAD directly for KB curation rather than assumed here.
Somatic vs. germline: All described genetic risk variants (PTPN22, HLA-DQB1, IL2RA, AIRE, PNPT1) are germline susceptibility alleles; there is no described somatic-mutation mechanism for AIG itself (somatic events become relevant only in the neoplastic complications — gNETs and gastric adenocarcinoma — as separate downstream processes).
Functional consequences: PTPN22 R620W disrupts a phosphatase involved in T-cell receptor signaling attenuation, lowering the threshold for autoreactive T-cell activation (loss of inhibitory function); AIRE variants impair thymic promiscuous gene expression and central tolerance induction, permitting escape of autoreactive T-cell clones (loss of function).
Modifier genes: BACH2 (broad Treg/Th differentiation modifier across autoimmune diseases) and SLC26A7/SLC26A9/SLC4A2 (ion transporters co-expressed with the H⁺/K⁺-ATPase, potentially modifying antigen exposure/epithelial stress) are proposed modifiers rather than primary drivers.
Epigenetics: Emerging but sparse data — aberrant DNA methylation patterns and altered microRNA profiles (miR-21 elevated, miR-223 reduced in gastric mucosa) are reported in AIG and associated with progression toward dysplasia/carcinoma, but comprehensive methylome/histone studies specific to AIG are lacking (a documented knowledge gap).
Chromosomal abnormalities: None described as causal for typical AIG; trisomy 21 (Down syndrome) carries a recognized comorbid association with autoimmune (including gastric) disease and pernicious anemia (case reports), reflecting broader autoimmune susceptibility rather than a specific gastric mechanism.

5. Environmental Information

Infectious trigger: Helicobacter pylori — proposed via molecular mimicry between its urease β-subunit and the gastric H⁺/K⁺-ATPase β-subunit; also implicated via chronic inflammation, polyclonal lymphocyte activation, epitope spreading, and bystander activation (MDPI 2025). Murine roseolovirus neonatal infection is a model-organism-demonstrated viral trigger (mouse), of uncertain human relevance.
Lifestyle: Smoking is an established independent/synergistic risk factor for gastric mucosal atrophy, intestinal metaplasia, and gastric cancer generally, relevant to AIG's malignant potential, though not shown to specifically initiate the autoimmune process. Diet/alcohol have not been robustly linked to AIG initiation specifically (as opposed to gastric cancer risk broadly).
Microbiome: Hypochlorhydria from parietal cell loss reshapes the gastric niche, permitting overgrowth of non-Helicobacter taxa (Streptococcus, Lactobacillus, Veillonella); dysbiosis-associated loss of short-chain-fatty-acid-producing species (e.g., Faecalibacterium prausnitzii) is hypothesized to impair Treg differentiation and worsen Th17-driven inflammation, and Bacillus cereus has been reported enriched specifically in AIG-related gastric cancer.
Occupational/toxin exposures: No specific validated occupational or toxin exposure is established for AIG.

6. Mechanism / Pathophysiology

Causal chain (upstream → downstream):

Genetic susceptibility (HLA-DRB1*03/*04, HLA-DQB1, PTPN22 R620W, AIRE variants, IL2RA, PNPT1) lowers central/peripheral tolerance thresholds →
Antigen exposure/trigger — possible H. pylori molecular mimicry of gastric H⁺/K⁺-ATPase β-subunit, or other unidentified triggers →
Autoreactive CD4+ T-cell activation: dendritic cells process H⁺/K⁺-ATPase peptides and, via IL-12/IL-23, drive differentiation into Th1 (IFN-γ, TNF-α) and Th17 (IL-17A/E/F, IL-21, IL-22) effector subsets; innate lymphoid cells (ILC3) reinforce IL-17/IL-22 output →
Cytotoxic effector mechanisms against parietal cells: (a) Fas upregulation on parietal cells + FasL-expressing T/NK cells assembling the death-inducing signaling complex (DISC) → caspase-8 activation; (b) perforin/granzyme B cytotoxicity from NK cells (~20% of gastric mucosal lymphocytes) and cytotoxic T cells; (c) B-cell-derived anti-parietal cell antibodies (PCA) targeting H⁺/K⁺-ATPase α/β-subunits and anti-intrinsic factor antibodies (IFA), mediating complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity →
Epithelial stress amplification: inflammatory cytokines (IL-1β, TNF-α) trigger ER stress/unfolded protein response via the PERK–eIF2α–ATF4–CHOP axis, downregulating Bcl-2 and activating Bax, driving mitochondrial-pathway apoptosis; impaired autophagic flux further sensitizes parietal cells to apoptosis (PMC12563516) →
Parietal cell loss → oxyntic (corpus/fundic) mucosal atrophy, with tissue remodeling sustained by gastric myofibroblasts and eosinophil infiltration; pseudopyloric and intestinal metaplasia develop as replacement phenotypes →
Loss of gastric acid (achlorhydria) removes the normal negative-feedback on antral G cells → chronic hypergastrinemia →
Gastrin–CCK2R signaling on ECL cells: activates ERK/MAPK (Ras-Raf-MEK-ERK → cyclin D1, c-Myc), PI3K/Akt (→ Bad inactivation, mTOR survival signaling), and STAT3 (→ Bcl-xL, VEGF) cascades, driving ECL cell hyperplasia, which can progress to dysplasia and type 1 gastric neuroendocrine tumors →
Loss of intrinsic factor (from parietal/IF-producing cell destruction, compounded by anti-IF antibodies blocking IF-B12 binding or the IF-B12-cubilin receptor interaction in the terminal ileum) → vitamin B12 malabsorption → megaloblastic pernicious anemia and, if prolonged, subacute combined degeneration of the spinal cord and peripheral neuropathy →
Chronic atrophic/metaplastic mucosa is an independent field of increased gastric adenocarcinoma risk (3–5× general population), compounding the ECL/gNET pathway.

Cell types involved (Cell Ontology candidates): parietal cell (CL:0000160), chief/zymogenic cell (CL:0000155), enterochromaffin-like cell (CL:0000502 or closest ECL-cell term), gastric mucous neck/foveolar cell, gastric G cell (gastrin-producing enteroendocrine cell), Th1 CD4+ T cell (CL:0000545-derived Th1 subset), Th17 CD4+ T cell, cytotoxic CD8+ T cell (CL:0000625), NK cell (CL:0000623), plasma/B cell (CL:0000786), dendritic cell (CL:0000451), ILC3 (CL:0001071), gastric myofibroblast, eosinophil (CL:0000771).

Biological processes (GO candidates): T-cell mediated cytotoxicity (GO:0001913), Fas signaling pathway (GO:0036337/apoptotic signaling via death domain receptors, GO:0008625), complement-dependent cytotoxicity, endoplasmic reticulum unfolded protein response (GO:0030968), regulation of apoptotic process (GO:0042981), autophagy (GO:0006914), positive regulation of interleukin-17 production (GO:0032740), cellular response to interferon-gamma (GO:0071346), response to gastrin (if modeled), MAPK cascade (GO:0000165), PI3K signaling (GO:0014065), regulation of vitamin B12 transport/intrinsic factor binding.

Molecular profiling: microRNA dysregulation (miR-21↑, miR-223↓) is reported in gastric mucosa; transcriptomic/proteomic/metabolomic single-cell or spatial datasets specific to AIG are not yet well established in public repositories (GEO/HCA) — an area flagged as an evidence gap in recent reviews.

Single-cell/advanced technologies: No mature single-cell atlas of human AIG gastric mucosa was identified in this search; this is an emerging-technology gap consistent with the "Human studies validating ER stress and autophagy dysfunction remain limited" caveat explicitly raised in the cellular-crosstalk review (PMC12563516).

7. Anatomical Structures Affected

Primary organ: Stomach, specifically the oxyntic mucosa of the corpus/fundus (UBERON:0001162 body of stomach / UBERON:0001156 gastric fundus), sparing the antrum (contrast with H. pylori-associated multifocal/antral-predominant gastritis).
Secondary organ involvement:
Hematologic system (bone marrow megaloblastic changes from B12 deficiency)
Nervous system (peripheral nerves, dorsal columns/lateral corticospinal tracts of the spinal cord — subacute combined degeneration)
Small intestine (terminal ileum, site of intrinsic-factor-mediated B12 absorption, secondarily affected functionally though not structurally)
Reproductive system (infertility/miscarriage reported)
Thyroid, pancreatic islets, skin/melanocytes (via associated autoimmune comorbidities, not direct AIG pathology)
Body systems: digestive, hematologic/immune, nervous, and (via comorbidity) endocrine and integumentary systems.
Tissue/cell level: gastric oxyntic (fundic) glands — parietal cells, chief cells, ECL cells, mucous neck cells; lamina propria immune infiltrate (T cells, B/plasma cells, eosinophils, mast cells); antral G cells (indirectly, via hypergastrinemia feedback, though G-cell hyperplasia itself can occur).
Subcellular level: mitochondria (apoptosis via Bax/Bcl-2, cytochrome c release), endoplasmic reticulum (UPR/PERK-eIF2α-ATF4-CHOP stress pathway), apical canalicular membrane of parietal cells (H⁺/K⁺-ATPase proton pump localization — GO Cellular Component: apical plasma membrane, GO:0016324).
Localization/laterality: Gastric involvement is typically diffuse within the corpus/fundus (not lateralized); neurological B12-deficiency manifestations can be bilateral and symmetric (peripheral neuropathy, subacute combined degeneration).

8. Temporal Development

Onset: Predominantly adult-onset, insidious; median diagnosis age 61–67 years (range 18–94). A distinct pediatric-onset phenotype exists (mean age 10.9 years, prevalence ~0.15% among biopsied children), often with strong concurrent extragastric autoimmunity.
Onset pattern: Chronic/insidious rather than acute; disease may be "silent" for years before serologic (PCA/IFA) positivity converts to histologic and clinical disease.
Progression/staging (histopathologic 3–5 stage models):
Stage 0 / "potential" AIG: seropositive (PCA/IFA+) but histologically normal or minimally abnormal.
Early phase: mild-to-moderate oxyntic atrophy, CD4+ lymphocytic infiltration, pseudopyloric metaplasia; parietal cells may show compensatory hypertrophy.
Florid phase: moderate-to-severe oxyntic gland atrophy, dense lymphoplasmacytic inflammation, ECL cell hyperplasia, intestinal metaplasia.
End-stage: severe gland loss, extensive intestinal metaplasia/dysplasia, ECL hyperplasia, paradoxically reduced active inflammation.
Progression rate: A prospective study of "potential" to "overt" AAG reported an annual progression rate of 10.9%; a separate 270-patient prospective cohort found histology progressed in essentially all patients within ~3 years with no spontaneous regression observed.
Disease course pattern: Monotonically progressive (not relapsing-remitting) at the histologic/immunologic level, though symptom burden can fluctuate.
Duration: Chronic, lifelong once established; the underlying autoimmune/atrophic process does not resolve spontaneously, though its hematologic and neurologic consequences (B12/iron deficiency) are effectively controlled with lifelong replacement therapy.
Critical periods: The seropositive "potential" phase represents a clinically important window for early detection before irreversible gland atrophy and before neurologic B12-deficiency sequelae become established; the pediatric-onset subgroup's long-term natural history remains largely unstudied (explicit knowledge gap).

9. Inheritance and Population

Epidemiology. - Prevalence: Estimated ~0.1–2% in the general population, rising to 2–3% in adults over 60. Endoscopic-biopsy cohort studies: USA (1988–2008, n=41,245 biopsies) ~1.1%; Japan (asymptomatic screening) ~0.49%; European multicenter gastritis cohorts ~2% among biopsied gastritis cases; lower prevalence reported in a large Chinese cohort (n=97,341) (Lenti et al., PMC8414617). - Ethnic/geographic variation: Non-white Hispanic populations show higher prevalence (~2.7%) versus ~1% in white, Asian, and African-American populations in some U.S. cohort data; earlier age of onset reported in non-white groups in some studies. - Sex ratio: Consistent female predominance, roughly 2–3:1 (F:M) across adult cohorts; the pediatric cohort shows an even more pronounced 68.2% female skew. - Age distribution: Bimodal-ish — a small pediatric-onset group (mean ~10.9 years) and the dominant adult/elderly-onset group (median 61–67 years).

Inheritance pattern: AIG is a complex/polygenic (multifactorial) trait, not Mendelian, driven by additive/interacting common variants (PTPN22, HLA-DQB1, IL2RA, PNPT1) plus environmental triggers. The exception is syndromic AIG occurring as one manifestation of monogenic autosomal recessive APS-1/APECED (biallelic AIRE loss-of-function), which follows classic Mendelian AR inheritance with high penetrance for the syndrome overall but variable penetrance/expressivity for the gastric component specifically.

Penetrance/expressivity: For the common polygenic form, individual risk-allele penetrance is low (as expected for GWAS-identified common variants, ORs 1.2–1.8); for AIRE-driven APS-1, the AIRE genotype has high penetrance for autoimmune polyendocrinopathy overall, but expressivity across specific component diseases (including AIG) is variable between AIRE-mutation carriers.

Genetic anticipation / mosaicism / founder effects: Not described for AIG's common polygenic form. AIRE founder mutations are known in specific populations (e.g., Finnish, Iranian Jewish, Sardinian founder alleles for APS-1), relevant to any AIG occurring in that syndromic context, but this is a population feature of APS-1 rather than of idiopathic AIG.

Consanguinity: Relevant only to the rare AR-AIRE/APS-1 syndromic route, not to typical polygenic AIG.

Carrier frequency: Not meaningfully defined for a polygenic trait; APS-1/AIRE carrier frequencies are population-specific and available via GeneReviews/GTR for that distinct monogenic condition.

Associated autoimmune comorbidity (polyautoimmunity): - Autoimmune thyroid disease: reported concurrently in 36–44% of AIG patients in some series (other sources cite ~2.8% in specific cohorts — figures vary substantially by study design/population, underscoring heterogeneity). - Type 1 diabetes: AIG/pernicious anemia risk in T1D patients is ~3–5× the general population; conversely, among T1D patients, 5–10% have AIG/pernicious anemia, 15–30% have autoimmune thyroid disease, 2–10% have vitiligo, and up to one-third develop a broader autoimmune polyglandular syndrome. - Vitiligo, rheumatoid arthritis, psoriasis, autoimmune hepatitis, myasthenia gravis, Sjögren syndrome, autoimmune hemolytic anemia are also reported comorbid associations, consistent with a "multiple autoimmune syndrome" (MAS) pattern (Autoimmune Institute review; PMC6146093 editorial). - Case reports also document AIG co-occurring with primary biliary cholangitis, non-nodal mantle cell lymphoma progression, and Down syndrome-associated pernicious anemia.

10. Diagnostics

Serologic tests (first-line, "serological biopsy" panel): - Anti-parietal cell antibodies (PCA): sensitivity ~81–90%, specificity ~88–90% (varies by assay/cohort). - Anti-intrinsic factor antibodies (IFA): lower sensitivity (~27–32%) but very high specificity (95–100%). - Newer ATP4A/ATP4B luciferase immunoprecipitation assays: ATP4A sensitivity ~75%/specificity ~88%; ATP4B sensitivity ~77%/specificity ~88% — proposed as improved, more standardized alternatives to conventional immunofluorescence PCA testing (Lenti/Massironi review, PMC11354099). - Serum pepsinogen I (PGI) and PGI/PGII ratio: low PGI (<70 µg/L, cutoffs vary by study) or low ratio (<2.1, <1.8, <3 depending on study/population) indicates oxyntic atrophy; sensitivity/specificity in the 67–100% range depending on cutoff and cohort. - Serum gastrin-17: elevated (>355 pg/mL in one study; various pmol/L cutoffs elsewhere) reflects loss of acid-mediated negative feedback and is a reliable marker of oxyntic atrophy; combined PGI/II + gastrin-17 panels reach ~88.9% accuracy for identifying NET-bearing patients. - Commercial panel: GastroPanel® (PGI, PGII, gastrin-17, H. pylori IgG) used for non-invasive screening. - Chromogranin A: elevated with ECL hyperplasia/NET development; used to monitor NET burden and treatment response (e.g., to netazepide/somatostatin analogs). - Novel immune marker: antral CD8+/CD4+ T-lymphocyte ratio >4.0 (sensitivity 71.4%, specificity 93.3%) proposed to distinguish AIG from H. pylori-associated gastritis histologically.

Endoscopy/histology (gold standard): - Endoscopic findings: sticky adherent mucus, scattered whitish protrusions, remnant oxyntic mucosal islands, patchy redness, hyperplastic polyps (in a 245-patient Japanese cohort). - Biopsy protocol: Updated Sydney System — minimum 5 biopsies (2 antrum, 1 incisura, 2 corpus) to allow topographic (corpus vs. antrum) comparison, essential to distinguish corpus-restricted AIG atrophy from antral-predominant H. pylori gastritis. - OLGA/OLGIM staging: combines topography with atrophy (OLGA) or intestinal metaplasia (OLGIM) severity into stages 0–IV; stage 0–II = lower cancer risk (surveillance every 3–5 years), stage III–IV = higher risk (surveillance every 1–2 years). - Histologic 3–5 stage model of disease progression as described in Section 8.

Differential diagnosis: H. pylori-associated (multifocal/antral-predominant) chronic gastritis; NSAID/chemical (reactive) gastropathy; other causes of iron/B12 deficiency (celiac disease, dietary deficiency, small intestinal bacterial overgrowth, pancreatic exocrine insufficiency, terminal ileal disease/resection); lymphocytic gastritis; Zollinger-Ellison syndrome (also causes hypergastrinemia, but via a gastrinoma rather than achlorhydria-driven feedback loss — distinguished by gastric pH/secretin stimulation testing).

Genetic testing: No first-line clinical genetic test is used for typical polygenic AIG (unlike Mendelian disorders); AIRE sequencing is indicated only when syndromic APS-1/APECED is clinically suspected (mucocutaneous candidiasis, hypoparathyroidism, adrenal insufficiency plus AIG).

Screening: No population-wide screening program exists for sporadic AIG; targeted serologic screening (PCA/IFA, pepsinogens) is reasonable in patients with unexplained iron or B12 deficiency, first-degree relatives of AIG patients, or patients with another organ-specific autoimmune disease (thyroid, T1D, vitiligo) given comorbidity rates.

11. Outcome/Prognosis

Mortality/survival: AIG itself is not directly fatal; prognosis is driven by (a) adequacy of B12/iron replacement and (b) surveillance for malignant complications. With appropriate lifelong vitamin replacement, hematologic and most neurologic manifestations are controlled or reversed if caught early.
Neurologic morbidity: Untreated/delayed B12 deficiency produces "inexorably progressive" neurologic injury (peripheral neuropathy → subacute combined degeneration → ataxia/weakness), which can become irreversible if replacement is delayed — underscoring the importance of early diagnosis.
Neoplastic risk/complications:
Type 1 gastric neuroendocrine tumors (gNETs): cumulative incidence ~2.8%/person-year in some cohorts, ~4.7% at 2 years in others; up to 10–37% prevalence in various case series depending on detection sensitivity and population; generally indolent — tumors <1 cm and Ki-67 ≤2% managed with surveillance; favorable prognosis overall, with <10% metastasis rate for lesions <2 cm.
Gastric adenocarcinoma: risk estimated at 3–5× (some sources: 7×) the general population; annual incidence ~0.1–0.5%/person-year; risk factors within the AIG population include age >60 (HR ~4.7), intestinal metaplasia without pseudopyloric metaplasia (HR ~4.3), and pernicious anemia (HR ~4.3). Notably, recent prospective cohorts restricted to H. pylori-negative AAG patients reported no gastric adenocarcinoma cases, suggesting that much of the historically reported cancer risk in AIG populations may be attributable to prior/concurrent H. pylori infection rather than the autoimmune process alone — an important nuance for risk stratification and a candidate HUMAN_MODEL_MISMATCH/knowledge-gap note.
Prognostic factors: age at diagnosis, degree of atrophy/OLGA-OLGIM stage, H. pylori status (past or present), presence of dysplasia, and B12-deficiency neurologic involvement at diagnosis.
Quality of life: Largely normalized with treatment in early-detected disease; unaddressed B12 deficiency and neuroendocrine tumor development are the main drivers of long-term morbidity.

12. Treatment

Pharmacotherapy (replacement/supportive): - Vitamin B12: lifelong intramuscular (or high-dose sublingual/oral) cyanocobalamin/hydroxocobalamin supplementation — first-line, definitive management of the pernicious-anemia component. MAXO candidate: pharmacotherapy generically, or a dietary/vitamin-supplementation MAXO term if available; NCIT:C15986 (Pharmacotherapy) with a CHEBI therapeutic_agent (e.g., CHEBI cyanocobalamin) is the dismech-pattern annotation. - Iron: oral iron (often with vitamin C to enhance absorption in the achlorhydric stomach) or, if oral therapy fails (due to hypochlorhydria-impaired absorption), intravenous iron infusion. Iron status should be checked in all AIG patients regardless of overt anemia, given corpus-predominant atrophy's impact on non-heme iron absorption. - Acid-suppressive therapy caution: PPIs are generally NOT recommended in AIG, since patients already have hypochlorhydria/achlorhydria and PPIs would exacerbate hypergastrinemia and ECL hyperplasia risk; H2-receptor antagonists (e.g., famotidine) are preferred if short-term acid-related symptom control is needed, and PPIs are reserved for short-term severe reflux esophagitis only.

Management of neoplastic complications: - Type 1 gNETs: small (<1 cm, Ki-67 ≤2%) lesions managed by endoscopic surveillance; larger (>1 cm) or higher-grade lesions undergo endoscopic resection (surveillance every 6–12 months post-resection per ESGE guidelines); refractory/recurrent cases may proceed to antrectomy (removes the gastrin-secreting antral mucosa, normalizing gastrin levels) or medical gastrin-pathway blockade. - Netazepide (a gastrin/CCK2-receptor antagonist): reduces chromogranin A and can shrink/eradicate type 1 gNETs in patients with autoimmune chronic atrophic gastritis, though continuous treatment is needed to prevent recurrence (PMC5306499). - Somatostatin analogs (e.g., octreotide, lanreotide): reported response rates ~25–100% for type 1 NETs across small studies. - Gastric adenocarcinoma: managed per standard gastric cancer oncologic pathways (endoscopic resection for early lesions, surgery/chemotherapy for advanced disease) — not AIG-specific.

Endoscopic surveillance: Regular high-definition upper endoscopy with systematic biopsy (per Sydney System protocol), frequency tailored to OLGA/OLGIM risk stage — every 3–5 years for low-risk (stage 0–II) and every 1–2 years for high-risk (stage III–IV) or NET-bearing patients.

Emerging/experimental: - Immunomodulatory therapy: limited evidence suggests corticosteroids or other immunosuppressants might help in early, highly inflammatory disease stages, though no targeted immunotherapy is currently approved. - Th17/IL-17-axis-targeted biologics (e.g., anti-IL-17 monoclonal antibodies like secukinumab/ixekizumab, approved in psoriasis/spondyloarthropathy) are mechanistically plausible given the Th17 contribution to AIG pathogenesis, but are not yet studied/approved specifically for AIG (an explicit translational gap). - Microbiota-targeted approaches: probiotic supplementation (e.g., Faecalibacterium prausnitzii) or fecal microbiota transplantation are proposed research directions to restore Treg-supportive short-chain-fatty-acid production, but remain preclinical/conceptual for AIG. - AI-assisted endoscopy: deep-learning-based image analysis reported to achieve diagnostic accuracy for atrophic changes comparable to or exceeding experienced endoscopists — an emerging diagnostic-support tool rather than a treatment.

Treatment algorithm summary: (1) confirm diagnosis serologically + histologically → (2) lifelong B12 replacement (parenteral) + iron repletion as needed → (3) OLGA/OLGIM-stratified endoscopic surveillance → (4) targeted intervention (endoscopic resection, antrectomy, netazepide/somatostatin analog) if type 1 gNET or dysplasia/adenocarcinoma develops → (5) screen for/monitor associated autoimmune comorbidities (thyroid, T1D, vitiligo).

13. Prevention

Primary prevention: No established primary prevention exists for the autoimmune initiation of AIG itself (unlike infectious or vaccine-preventable disease); H. pylori eradication in infected individuals is standard gastritis/gastric-cancer prevention practice generally, though its specific effect on preventing AIG onset is unproven and the relationship is complex (see Section 5).
Secondary prevention (early detection): Targeted serologic screening (PCA/IFA, pepsinogen, gastrin-17) in high-risk groups — first-degree relatives of AIG patients, patients with unexplained iron/B12 deficiency, and patients with another organ-specific autoimmune disease (autoimmune thyroiditis, type 1 diabetes, vitiligo) — enables detection at the "potential"/seropositive stage before irreversible atrophy or neurologic injury.
Tertiary prevention: Structured endoscopic surveillance (OLGA/OLGIM-stratified) prevents progression from dysplasia to invasive gastric adenocarcinoma and enables early resection of type 1 gNETs before they enlarge or (rarely) metastasize; lifelong B12/iron replacement prevents irreversible hematologic and neurologic complications.
Genetic counseling: Relevant primarily in the rare monogenic APS-1/AIRE-driven syndromic context (recurrence risk counseling for autosomal recessive AIRE variants), not for typical sporadic polygenic AIG.
Public health: No population-level public health intervention (vaccination, sanitation) is applicable; the closest public-health-relevant lever is H. pylori screening/eradication programs in high-gastric-cancer-incidence regions, which have ancillary relevance to the atrophic-gastritis-to-cancer pathway generally.

14. Other Species / Natural Disease

Taxonomy: Naturally occurring/experimentally induced autoimmune gastritis has been most extensively studied in mouse (Mus musculus, NCBITaxon:10090).
Natural/spontaneous disease in animals: C3H/He mice develop spontaneous autoimmune gastritis without experimental manipulation, serving as a natural-disease model for gastric autoimmunity (PMID: 9777963).
Veterinary relevance: No major companion-animal or livestock natural-disease correlate of human AIG was identified in this search; the mouse models above are laboratory rather than veterinary-clinical observations.
Orthologous genes: Mouse Atp4a/Atp4b (orthologs of human ATP4A/ATP4B) are the principal autoantigens in murine models, directly paralleling the human disease target.
Comparative pathology: Murine neonatal-thymectomy-induced gastritis is histologically and immunologically similar to human pernicious-anemia-associated atrophic gastritis — chronic mononuclear infiltrate, destruction of parietal and zymogenic (chief) cells, and autoantibodies to H⁺/K⁺-ATPase α- and β-subunits (PMID: 1648525; PMID: 9272282).
Zoonotic potential: Not applicable — AIG is a non-infectious autoimmune process, not a transmissible disease.

15. Model Organisms

Neonatal thymectomy mouse model: ~60% of neonatally thymectomized BALB/c mice spontaneously develop autoimmune gastritis, driven by depletion of CD4+CD25+ regulatory T cells; histologically and serologically similar to human pernicious-anemia-associated gastritis, with autoantibodies against H⁺/K⁺-ATPase α- and β-subunits (Clinical and Experimental Immunology; PMID: 1648525, PMID: 9272282). The thymic (rather than purely gastric) expression pattern of the α-subunit in BALB/c thymus is proposed to explain the dominant pathogenic role of the β-subunit.
Spontaneous C3H/He mouse model: A genetically distinct strain (C3H/He) develops autoimmune gastritis spontaneously without thymectomy, offering a complementary "new mouse model for gastric autoimmunity" (PMID: 9777963).
Immunization-induced model: Immunization of mice with purified gastric H⁺/K⁺-ATPase induces a reversible autoimmune gastritis, useful for dissecting antigen-specific initiation and potential resolution/tolerance mechanisms (PMC1363986).
TxA23 TCR-transgenic / polyclonal effector T-cell transfer models: Adoptive transfer of H⁺/K⁺-ATPase-specific effector T cells (including Th1, Th2, and Th17 subsets) produces autoimmune gastritis with distinct histopathologic patterns and differential susceptibility to suppression by regulatory T cells depending on the transferred effector subset (PMC2561289) — this system has been particularly informative for dissecting how Th1 vs. Th17-driven disease differs mechanistically and in Treg-responsiveness, directly informing the Th17/Treg-axis therapeutic hypotheses discussed in Section 12.
Model characteristics/limitations: Mouse models robustly recapitulate the core autoantigen (H⁺/K⁺-ATPase), the T-cell-mediated destructive mechanism, and downstream atrophic/metaplastic histology, but do not fully model the human-specific downstream consequences — chronic ECL hyperplasia progressing to type 1 gastric NETs and long-term gastric adenocarcinoma risk are less consistently reproduced in short-lived rodent models, and human-specific comorbid polyautoimmunity (thyroid, T1D, vitiligo clustering) is not intrinsically modeled by single-antigen mouse systems. This human-model translational gap (mouse captures initiation/parietal-cell-destruction biology well, but not the full human neoplastic-complication trajectory) is a strong candidate for a HUMAN_MODEL_MISMATCH discussion in a dismech KB entry.
Research applications: These models have been used to define the H⁺/K⁺-ATPase α/β-subunit antigenic hierarchy, the CD4+CD25+ Treg-dependent tolerance mechanism, and differential Th1/Th2/Th17 pathogenicity and Treg-suppressibility — directly supporting current human therapeutic hypotheses around Treg restoration and Th17-cytokine blockade.
Resources: MGI (Mouse Genome Informatics) for Atp4a/Atp4b strain and allele records; no dedicated ZFIN/FlyBase/WormBase model of autoimmune gastritis was identified (unsurprising, as gastric parietal cell autoimmunity is a mammalian-immune-system-dependent phenomenon without a clear invertebrate correlate).

Summary of Key Ontology Term Suggestions for KB Curation

Genes (HGNC): ATP4A (hgnc:816), ATP4B (hgnc:817), GIF (hgnc:4256), PTPN22 (hgnc:9646), PNPT1 (hgnc:23349), HLA-DQB1 (hgnc:4944), IL2RA (hgnc:6008), AIRE (hgnc:360), BACH2 (hgnc:939)
Cell types (CL): parietal cell, chief cell, enterochromaffin-like cell, gastric G cell, Th1/Th17 CD4+ T cell, NK cell, plasma cell, dendritic cell
Biological processes (GO): T-cell mediated cytotoxicity, Fas-mediated apoptosis, ER stress/UPR, autophagy, IL-17 production, MAPK cascade, PI3K-Akt signaling
Phenotypes (HP): megaloblastic anemia, iron deficiency anemia, subacute combined degeneration, ataxia, glossitis, dyspepsia, neuroendocrine neoplasm
Anatomy (UBERON): body of stomach/gastric fundus (oxyntic mucosa), antrum, spinal cord dorsal columns
Chemicals (CHEBI): cyanocobalamin/hydroxocobalamin, ferrous sulfate, netazepide
Treatments (MAXO/NCIT): NCIT:C15986 (Pharmacotherapy) + therapeutic_agent for B12/iron; endoscopic resection/surveillance (MAXO surgical/procedural terms)

Important caveat for curation: I was unable to definitively confirm a dedicated MONDO/OMIM identifier specifically for "autoimmune gastritis" as distinct from pernicious anemia (ORPHA:120) during this search — recommend an explicit OAK/MONDO-browser lookup (runoak -i sqlite:obo:mondo search "autoimmune gastritis") before committing any mappings: block to a disorder YAML, per the project's anti-hallucination ontology-verification SOP.